A follow-up to "Anti-cytokine therapy in chronic destructive arthritis" by Wim B van den Berg
AUTOR(ES)
Brennan, Fionula M
FONTE
BioMed Central
RESUMO
In recent years, the effectiveness of anti-TNF therapy in treating rheumatoid arthritis (RA) has become apparent. While trials of IL-1 receptor antagonist in RA have been encouraging, it clearly is more difficult to target two molecules (IL-1 α and β) than one (TNF-α). In his review article, Professor Wim van den Berg argues that both TNF-α and IL-1 must be blocked in RA and that although TNF is clearly a potent inflammatory molecule, the dominant cytokine in the subsequent degradation of the joint tissue is IL-1. This commentary discusses his hypothesis in light of animal studies and the limitations of the conclusions that can be drawn from them. More broadly, it discusses the biology of TNF-α and IL-1 and suggests explanations of why TNF-α is a pivotal cytokine in this disease.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=128897Documentos Relacionados
- Response to Fionula Brennan's Commentary "A follow-up to 'Anti-cytokine therapy in chronic destructive arthritis' by Wim B van den Berg"
- Anti-cytokine therapy in chronic destructive arthritis
- Psoriatic arthritis. Follow-up study.
- Chronic Bronchitis: A Five-year Follow-up
- Chronic bronchitis: a 10-year follow-up
